{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58","upperLimit":"193","value":"98"},{"groupId":"OG001","lowerLimit":"61","upperLimit":"262","value":"105"},{"groupId":"OG002","lowerLimit":"63","upperLimit":"155","value":"101"},{"groupId":"OG003","lowerLimit":"61","upperLimit":"155","value":"111"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients will receive a second transplant according to treatment assignments.","dispersionType":"Full Range","groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients","id":"OG000","title":"Auto-Auto Standard Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"OG001","title":"Auto-Allo Standard Risk"},{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients","id":"OG002","title":"Auto-Auto High Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients","id":"OG003","title":"Auto-Allo High Risk"}],"paramType":"MEDIAN","populationDescription":"Patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Year 1","title":"Interval From First to Second Transplantation","type":"SECONDARY","unitOfMeasure":"days"}